oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Cladribine prolongs progression-free survival and time to second treatment compared to fludarabine and high-dose chlorambucil in chronic lymphocytic leukemia
Department of Haematology, Royal North Shore Hospital, St LeonardsSydney, NSW, Australia .
Department of Hematology, University Hospital, Linköping, Sweden; Department of Hematology, Skåne University Hospital, Lund, Sweden .
Department of Oncology, Karolinska University Hospital, Stockholm, Sweden .
Department of Hematology, National Hospital, Copenhagen, Denmark .
Show others and affiliations
2014 (English)In: Leukemia and Lymphoma, ISSN 1042-8194, E-ISSN 1029-2403, Vol. 55, no 12, 2769-2777 p.Article in journal (Refereed) Published
Abstract [en]

We conducted a randomized phase III trial to compare the efficacy and safety of two purine analogs, cladribine and fludarabine, with high-dose chlorambucil, in patients with previously untreated chronic lymphocytic leukemia (CLL). Between 1997 and 2004, 223 patients with CLL were randomly assigned to cladribine, fludarabine or chlorambucil, for six cycles of therapy with frequent health-related quality of life assessments. There was no statistical difference for the primary endpoint of overall response with cladribine (70%), fludarabine (67%) and chlorambucil (59%), or complete remission (12%, 7% and 8%), respectively. However, the median progression-free survival (25, 10, 9 months) and median time to second treatment (40, 22, 21 months) were superior with cladribine. There was no significant difference in overall survival (96, 82 and 91 months), nor in toxicity or HRQoL assessments. Monotherapy with cladribine gives superior PFS and longer response duration than fludarabine and chlorambucil as first-line treatment of CLL.

Place, publisher, year, edition, pages
Informa Healthcare, 2014. Vol. 55, no 12, 2769-2777 p.
Keyword [en]
Lymphoid leukemia, chemotherapeutic approaches, pharmacotherapeutics, CLL
National Category
Cancer and Oncology Hematology
Research subject
Oncology
Identifiers
URN: urn:nbn:se:oru:diva-37788DOI: 10.3109/10428194.2014.893306ISI: 000346571100016PubMedID: 24524339Scopus ID: 2-s2.0-84919414874OAI: oai:DiVA.org:oru-37788DiVA: diva2:756390
Available from: 2014-10-17 Created: 2014-10-15 Last updated: 2017-10-18Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Uggla, Bertil
By organisation
Örebro University Hospital
In the same journal
Leukemia and Lymphoma
Cancer and OncologyHematology

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 291 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf